Combination treatment with aripiprazole and valproic acid for acute mania: An 8-week, single-blind, randomized controlled trial

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 97-102

  Jeong, Hyun Ghang ^a   Lee, Moon Soo ^a   Ko, Young Hoon ^b   Han, Changsu ^b   Jung, In Kwa ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

adverse effect; aripiprazole; bipolar disorder; combination treatment; efficacy; haloperidol; valproic acid

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; VALPROIC ACID;

ACUTE MANIA; ADJUVANT THERAPY; ADULT; AKATHISIA; ALLERGIC REACTION; ARTICLE; BLURRED VISION; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DREAMING; DRUG EFFICACY; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOMS SCALE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; HYPERSALIVATION; LIBIDO; LIVERPOOL UNIVERSITY NEUROLEPTIC SIDE EFFECT RATING SCALE; MALE; MANIA; MEMORY DISORDER; MENTAL DISEASE; MUSCLE RIGIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VALPROIC ACID; WEIGHT GAIN; YOUNG ADULT;

EID: 84861510494     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182560401     Document Type: Article

References (34)

1. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680Y690.
2. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
3. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-242.
4. Muller-Oerlinghausen B, Retzow A, Henn FA, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20:195Y203.
5. Yatham LN, Kennedy SH, O'DonoVan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7(Suppl 3):5Y69.
6. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):28Y36.
7. Aitchison KJ, Bienroth M, Cookson J, et al. A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol 2009;23:231Y240.
8. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother 2007;8:1001Y1009.
9. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381Y389.
10. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375Y383.
11. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45Y53.
12. Vieta E, T'Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165:1316Y1325.
13. Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133Y144.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diosrders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
15. Inada T, Yagi G. Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci 1995;49:239Y244.
16. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage. Tokyo, Japan: Seiwa Shoten; 1996.
17. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650Y653.
18. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62Y69.
19. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146Y1154.
20. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141Y147.
21. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213Y223.
22. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599Y606.
23. Keck PE, Jr., Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651Y1658.
24. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112:36Y49.
25. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536Y546.
26. Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 2009;8:373Y386.
27. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009;29:165Y169.
28. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172Y177.
29. Chengappa KN, Chalasani L, Brar JS, et al. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002;24:1576Y1584.
30. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65Y69.
31. Verrotti A, D'Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011;12:e32Ye43.
32. Pae CU, Serretti A, Patkar AA, et al. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367Y388.
33. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048Y1056.
34. Vieta E, Owen R, Baudelet C, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010;26:1485Y1496.